Revolution Medicines, INC Form 4 insider transactions

Mark A. Goldsmith, CEO of Revolution Medicines, sold shares of common stock to cover tax withholding obligations upon the vesting of restricted stock units.

Chief Financial Officer of Revolution Medicines, Jack Anders, sold 1,261 shares of common stock on March 18, 2024, to cover tax obligations related to vesting restricted stock units.

Margaret Horn, Chief Operating Officer of Revolution Medicines, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Margaret Horn, Chief Operating Officer of Revolution Medicines, reports the acquisition of 41,000 shares of common stock and 143,500 stock options.

Mark Goldsmith, CEO of Revolution Medicines, reports the acquisition of 90,000 common stock shares and 314,000 stock options, alongside adjustments to existing holdings.

Jeff Cislini, General Counsel of Revolution Medicines, reports the acquisition of 21,000 shares of common stock and 73,500 stock options.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, acquired 51,400 shares of common stock and 179,900 stock options on March 1, 2024.

Jack Anders, CFO of Revolution Medicines, reports acquiring 26,400 shares of common stock and 92,400 stock options on March 1, 2024.

Xiaolin Wang, an officer at Revolution Medicines, acquired shares and stock options in the company on March 1, 2024.